Experiences of oral pre-exposure prophylaxis (PrEP) use disclosure among South African adolescent girls and young women and its perceived impact on adherence

被引:50
作者
Giovenco, Danielle [1 ,2 ]
Gill, Katherine [2 ]
Fynn, Lauren [2 ]
Duyver, Menna [2 ]
O'Rourke, Shannon [3 ]
van der Straten, Ariane [3 ,4 ]
Morton, Jennifer F. [5 ]
Celum, Connie L. [5 ,6 ,7 ]
Bekker, Linda-Gail [2 ]
机构
[1] Univ North Carolina Chapel Hill, Dept Epidemiol, Chapel Hill, NC 27599 USA
[2] Univ Cape Town, Desmond Tutu HIV Ctr, Cape Town, South Africa
[3] RTI Int, Womens Global Hlth Imperat, Berkeley, CA USA
[4] UCSF, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA USA
[5] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA
[6] Univ Washington, Dept Med, Seattle, WA USA
[7] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1371/journal.pone.0248307
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Introduction There is limited understanding of how social dynamics impact pre-exposure prophylaxis (PrEP) adherence among adolescent girls and young women (AGYW) in generalized HIV-epidemic settings. We examined experiences of oral PrEP use disclosure to various social groups with the goal of identifying supportive relationships that can be leveraged to promote adherence. Methods We used qualitative methods to explore experiences disclosing PrEP use and the perceived impact of disclosure on adherence among 22 South African AGYW (16-25 years) taking daily oral PrEP. Serial in-depth-interviews (IDIs) were conducted 1-, 3-, and 12-months post-PrEP initiation. Respondents also self-reported their disclosures separately for various social groups and adherence was assessed using intracellular tenofovir-diphosphate levels. Results Qualitative respondents had a median age of 20.5 years and reported disclosing their PrEP use to friends (n = 36 total disclosures), partners, siblings, other family members (n = 24 disclosures each), and parents (n = 19 disclosures). IDI data revealed that parents and partners provided the most support to respondents and a lack of support from these groups was most often perceived as negatively affecting PrEP use. AGYW described difficulties explaining PrEP to their mothers, who believed PrEP was HIV treatment or would lead to HIV infection. Disclosure to household members was notably meaningful for AGYW (both positively and negatively). Respondents reported leveraging supportive relationships for pill reminders. For respondents who perceived a household member would be unsupportive, however, non-disclosure was less feasible and PrEP use was often stigmatized. To avoid stigma, several respondents hid or discontinued PrEP. Conclusions While supportive relationships may facilitate PrEP use, disclosure can also lead to stigma. Counselors should support AGYW in disclosing to key people in their social networks and provide AGYW with materials that lend credibility to explanations of PrEP. Community education is necessary to alleviate PrEP-related stigma and facilitate disclosure.
引用
收藏
页数:13
相关论文
共 20 条
[1]   Experiences with HPTN 067/ADAPT Study-Provided Open-Label PrEP Among Women in Cape Town: Facilitators and Barriers Within a Mutuality Framework [J].
Amico, K. Rivet ;
Wallace, Melissa ;
Bekker, Linda-Gail ;
Roux, Surita ;
Atujuna, Millicent ;
Sebastian, Elaine ;
Dye, Bonnie J. ;
Elharrar, Vanessa ;
Grant, Robert M. .
AIDS AND BEHAVIOR, 2017, 21 (05) :1361-1375
[2]   Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy [J].
Anderson, Peter L. ;
Liu, Albert Y. ;
Castillo-Mancilla, Jose R. ;
Gardner, Edward M. ;
Seifert, Sharon M. ;
McHugh, Cricket ;
Wagner, Theresa ;
Campbell, Kayla ;
Morrow, Mary ;
Ibrahim, Mustafa ;
Buchbinder, Susan ;
Bushman, Lane R. ;
Kiser, Jennifer J. ;
MaWhinney, Samantha .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2018, 62 (01)
[3]  
[Anonymous], 2016, AIDS BY THE NUMBERS
[4]   Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial [J].
Celum, Connie L. ;
Gill, Katherine ;
Morton, Jennifer F. ;
Stein, Gabrielle ;
Myers, Laura ;
Thomas, Katherine K. ;
McConnell, Margaret ;
van der Straten, Ariane ;
Baeten, Jared M. ;
Duyver, Menna ;
Mendel, Eve ;
Naidoo, Keshani ;
Dallimore, Jacqui ;
Wiesner, Lubbe ;
Bekker, Linda-Gail .
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 (11)
[5]   Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial [J].
Corneli, Amy ;
Perry, Brian ;
Agot, Kawango ;
Ahmed, Khatija ;
Malamatsho, Fulufhelo ;
Van Damme, Lut .
PLOS ONE, 2015, 10 (04)
[6]   Effectiveness and safety of oral HIV preexposure prophylaxis for all populations [J].
Fonner, Virginia A. ;
Dalglish, Sarah L. ;
Kennedy, Caitlin E. ;
Baggaley, Rachel ;
O'Reilly, Kevin R. ;
Koechlin, Florence M. ;
Rodolph, Michelle ;
Hodges-Mameletzis, Ioannis ;
Grant, Robert M. .
AIDS, 2016, 30 (12) :1973-1983
[7]   Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial [J].
Gill, Katherine ;
Johnson, Leigh ;
Dietrich, Janan ;
Myer, Landon ;
Marcus, Rebecca ;
Wallace, Melissa ;
Pidwell, Tanya ;
Mendel, Eve ;
Fynn, Lauren ;
Jones, Kai ;
Wiesner, Lubbe ;
Slack, Catherine ;
Strode, Ann ;
Spiegel, Hans ;
Hosek, Sybil ;
Rooney, James ;
Gray, Glenda ;
Bekker, Linda-Gail .
LANCET CHILD & ADOLESCENT HEALTH, 2020, 4 (12) :875-883
[8]   PrEP Stigma: Implicit and Explicit Drivers of Disparity [J].
Golub, Sarit A. .
CURRENT HIV/AIDS REPORTS, 2018, 15 (02) :190-197
[9]   Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study [J].
Grant, Robert M. ;
Anderson, Peter L. ;
McMahan, Vanessa ;
Liu, Albert ;
Amico, K. Rivet ;
Mehrotra, Megha ;
Hosek, Sybil ;
Mosquera, Carlos ;
Casapia, Martin ;
Montoya, Orlando ;
Buchbinder, Susan ;
Veloso, Valdilea G. ;
Mayer, Kenneth ;
Chariyalertsak, Suwat ;
Bekker, Linda-Gail ;
Kallas, Esper G. ;
Schechter, Mauro ;
Guanira, Juan ;
Bushman, Lane ;
Burns, David N. ;
Rooney, James F. ;
Glidden, David V. .
LANCET INFECTIOUS DISEASES, 2014, 14 (09) :820-829
[10]  
GROTEVANT HD, 1985, CHILD DEV, V56, P415, DOI 10.1111/j.1467-8624.1985.tb00116.x